Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Portland Investment Counsel Inc.

Portland Investment Counsel Inc. increased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report) by 33.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 40,000 shares of the biotechnology company’s stock after purchasing an additional 10,000 shares during the quarter. Portland Investment Counsel Inc.’s holdings in Iovance Biotherapeutics were worth $376,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. ORG Partners LLC purchased a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth approximately $32,000. Quest Partners LLC increased its position in Iovance Biotherapeutics by 1,237.7% during the second quarter. Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock worth $40,000 after buying an additional 4,629 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new position in shares of Iovance Biotherapeutics in the second quarter worth $58,000. Daiwa Securities Group Inc. lifted its position in shares of Iovance Biotherapeutics by 754.0% in the second quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 7,781 shares in the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in shares of Iovance Biotherapeutics during the third quarter valued at $89,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Stock Down 0.9 %

Shares of NASDAQ IOVA opened at $9.32 on Friday. The stock has a market capitalization of $2.84 billion, a PE ratio of -6.31 and a beta of 0.60. The firm has a fifty day moving average of $9.84 and a 200-day moving average of $9.48. Iovance Biotherapeutics, Inc. has a 52-week low of $5.76 and a 52-week high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVAGet Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The firm had revenue of $58.56 million during the quarter, compared to the consensus estimate of $53.54 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. During the same quarter in the previous year, the business earned ($0.46) earnings per share. Equities research analysts expect that Iovance Biotherapeutics, Inc. will post -1.25 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Ryan D. Maynard sold 50,000 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total value of $503,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $75,450. This trade represents a 86.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 12.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. StockNews.com upgraded shares of Iovance Biotherapeutics to a “sell” rating in a report on Monday, August 12th. UBS Group initiated coverage on shares of Iovance Biotherapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.33.

Read Our Latest Stock Report on IOVA

Iovance Biotherapeutics Company Profile

(Free Report)

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

Read More

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.